Hester Biosciences Ltd Stock Price Today (NSE: HESTERBIO)
Fundamental Score
Hester Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Hester Biosciences Ltd share price today is ₹1259.10, down 4.49% on NSE/BSE as of 30 March 2026. Hester Biosciences Ltd (HESTERBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.40K (Cr). The 52-week high for HESTERBIO share price is ₹2350.00 and the 52-week low is ₹1268.00. At a P/E ratio of 32.04x, HESTERBIO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 9.18% and a debt-to-equity ratio of 0.63.
Hester Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Hester Biosciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Hester Biosciences Share Price: A Financial Stability Analysis
The pharmaceutical industry is currently experiencing a period of nuanced growth, driven by increasing healthcare awareness and evolving disease patterns, particularly in the veterinary sector. This analysis examines the financial stability of Hester Biosciences Ltd, focusing on its current market standing. At the time of this analysis, the Hester Biosciences share price stands at ₹1509.5, with a Price-to-Earnings (PE) ratio of 32.04 and a Return on Capital Employed (ROCE) of 9.71%. This data, alongside peer comparisons, offers valuable insights into the company's financial health.
A crucial metric for evaluating a company's efficiency is its ROCE. Hester Biosciences Ltd's ROCE of 9.71% indicates the profitability generated from its invested capital. While seemingly reasonable, this figure should be compared against industry averages and the company's historical performance to gauge its true strength. A higher ROCE generally signifies a stronger competitive advantage or "moat," reflecting efficient capital allocation and potential for future growth. A lower ROCE might suggest inefficiencies or increased competition eroding profitability.
When compared to sector peers, Hester Biosciences Ltd’s valuation reveals further perspective. Consider
Mankind Pharma Ltd, a company known for its established brand and robust distribution network. While a detailed comparison of management quality requires deeper qualitative analysis, focusing on factors like leadership experience, strategic decision-making, and corporate governance, examining these aspects helps assess the potential impact on long-term performance and shareholder value. A contrast of management effectiveness across peer groups can highlight relative strengths and weaknesses within Hester Biosciences Ltd.The PE ratio of 32.04 suggests that the market has relatively high expectations for Hester Biosciences Ltd's future earnings. It would be prudent to evaluate the sustainability of this valuation, considering factors like future growth prospects, industry trends, and potential risks. This financial analysis is part of an 80-parameter fundamental audit of Hester Biosciences Ltd, verified by Sweta Mishra, and is intended for informational purposes only. This is an observation-based analysis and does not constitute financial advice or a recommendation to buy or sell shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Hester Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HESTERBIO across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (22.12%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (76.22%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (10.32x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (53.73%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (9.18%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.71%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-15.20%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-0.72% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.72% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-55.57 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.53%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Hester Biosciences Ltd Financial Statements
Comprehensive financial data for Hester Biosciences Ltd including income statement, balance sheet and cash flow
About HESTERBIO (Hester Biosciences Ltd)
Hester Biosciences Ltd is a dynamic pharmaceutical company dedicated to safeguarding animal health through innovative solutions. They specialize in the development, manufacturing, ...and distribution of a comprehensive range of veterinary vaccines and animal health products, catering to both domestic and international markets. With a commitment to preventing diseases and improving livestock productivity, Hester Biosciences operates through dedicated divisions focused on Poultry Healthcare and Animal Healthcare. These divisions work synergistically to deliver tailored solutions addressing the unique needs of different animal species and farming practices. The company's dedication to research and development drives the creation of cutting-edge vaccines, ensuring effective protection against prevalent and emerging animal diseases. Hester Biosciences' Poultry Healthcare segment provides a wide array of vaccines, specifically formulated to protect poultry flocks from debilitating diseases. The company offers vaccines against Newcastle disease, a highly contagious viral infection, as well as Infectious Bronchitis, a respiratory illness affecting poultry. Their product portfolio also includes vaccines for Infectious Bursal disease, Fowl Pox, Marek's disease, Infectious Coryza, Fowl Cholera, Inclusion Body Hepatitis, Fowl Typhoid, and Avian Encephalomyelitis. These vaccines are designed to stimulate the immune system of poultry, providing robust protection against these common diseases and improving overall flock health and productivity. Hester Biosciences is deeply invested in the poultry industry's success and actively supports farmers in maintaining healthy and profitable operations. Beyond poultry, Hester Biosciences' Animal Healthcare segment is dedicated to developing and distributing vaccines for livestock. These vaccines are designed to protect animals from Peste des Petits Ruminants (PPR), a devastating disease affecting small ruminants. In addition to vaccines, the company also offers animal health products, providing holistic solutions for animal welfare. Hester Biosciences focuses on building strong relationships with veterinarians and farmers, delivering specialized support and assistance to enhance animal health outcomes. By providing quality vaccines and animal health products, Hester Biosciences contributes to improved animal health and sustainable livestock production, ultimately benefiting farmers and consumers alike.
Company Details
Key Leadership
Corporate Events
HESTERBIO Share Price: Frequently Asked Questions
What is the current share price of Hester Biosciences Ltd (HESTERBIO)?
As of 30 Mar 2026, 12:02 pm IST, Hester Biosciences Ltd share price is ₹1259.10. The HESTERBIO stock has a market capitalisation of ₹1.40K (Cr) on NSE/BSE.
Is HESTERBIO share price Overvalued or Undervalued?
HESTERBIO share price is currently trading at a P/E ratio of 32.04x, compared to the industry average of 31.77x. Based on this relative valuation, the Hester Biosciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of HESTERBIO share price?
The 52-week high of HESTERBIO share price is ₹2350.00 and the 52-week low is ₹1268.00. These values are updated daily from NSE/BSE price data.
What factors affect the Hester Biosciences Ltd share price?
Key factors influencing HESTERBIO share price include quarterly earnings growth (Sales Growth: -15.20%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Hester Biosciences Ltd a good stock for long-term investment?
Hester Biosciences Ltd shows a 5-year Profit Growth of -0.72% and an ROE of 9.18%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.63 before investing in HESTERBIO shares.
How does Hester Biosciences Ltd compare with its industry peers?
Hester Biosciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare HESTERBIO share price P/E of 32.04x and ROE of 9.18% against the industry averages to determine competitive standing.
What is the P/E ratio of HESTERBIO and what does it mean?
HESTERBIO share price has a P/E ratio of 32.04x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.
How is HESTERBIO performing according to Bull Run's analysis?
HESTERBIO has a Bull Run fundamental score of 35.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does HESTERBIO belong to?
HESTERBIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Hester Biosciences Ltd share price.
What is Return on Equity (ROE) and why is it important for HESTERBIO?
HESTERBIO has an ROE of 9.18%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Hester Biosciences Ltd generates profits from shareholders capital.
How is HESTERBIO debt-to-equity ratio and what does it indicate?
HESTERBIO has a debt-to-equity ratio of 0.63, which indicates moderate leverage that should be monitored.
What is HESTERBIO dividend yield and is it a good dividend stock?
HESTERBIO offers a dividend yield of 0.43%, meaning you receive ₹0.43 annual dividend for every ₹100 invested in Hester Biosciences Ltd shares.
How has HESTERBIO share price grown over the past 5 years?
HESTERBIO has achieved 5-year growth rates of: Sales Growth 11.16%, Profit Growth -0.72%, and EPS Growth -0.72%.
What is the promoter holding in HESTERBIO and why does it matter?
Promoters hold 53.73% of HESTERBIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Hester Biosciences Ltd.
What is HESTERBIO market capitalisation category?
HESTERBIO has a market capitalisation of ₹1405 crores, placing it in the Small-cap category.
How volatile is HESTERBIO stock?
HESTERBIO has a beta of N/A. A beta > 1 suggests the Hester Biosciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is HESTERBIO operating profit margin trend?
HESTERBIO has a 5-year average Operating Profit Margin (OPM) of 22.12%, indicating the company's operational efficiency.
How is HESTERBIO quarterly performance?
Recent quarterly performance shows Hester Biosciences Ltd YoY Sales Growth of -15.20% and YoY Profit Growth of 76.22%.
What is the institutional holding pattern in HESTERBIO?
HESTERBIO has FII holding of 0.53% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Hester Biosciences Ltd stock.